FINWIRES · TerminalLIVE
FINWIRES

Bravo Mining股价上涨1.4%，此前该公司公布了巴西Luanga项目的最新化验结果。

By

-- Bravo Mining (BRVO.V) 周二公布了巴西 Luanga 钯铂铑金镍矿床中央区和新近勘探的新月区八个钻孔的化验结果。 亮点包括：70 米厚的矿层，铂族金属和金 (PGM+Au) 品位为 1.9 克/吨，镍含量为 0.28%；其中 20 米厚的矿层，PGM+Au 品位为 3.6 克/吨，镍含量为 0.40%；19 米厚的矿层，PGM+Au 品位为 3.2 克/吨；以及 8 米厚的矿层，铜含量为 1.94%，PGM+Au 品位为 0.6 克/吨。 Bravo 表示，这些结果继续表明 Luanga 矿床的矿产资源具有扩大和升级的潜力。该公司还补充说，迄今为止已完成 400 个钻孔，其中 355 个钻孔的结果已公布，另有 37 个钻孔的化验结果待公布。 “加密钻探持续截获厚度和品位均与早期钻探结果相当甚至更优的矿体。本新闻稿中的钻探剖面图也表明，品位持续稳定，钻孔间和剖面间的连续性极佳，”董事长兼首席执行官路易斯·阿泽维多 (Luis Azevedo) 表示。“新月形矿带 (Crescent Zone) 的积极成果也令我们倍感鼓舞。该矿带是位于卢安加 (Luanga) 三大铂族金属矿区之外的区域性目标。新月形矿带是在 2025 年地球物理勘测完成后，通过重新解释和重新测井而划定的。此外，我们在新月形矿带东端还发现了一处令人鼓舞的铜矿点 (DDH26LU307)，值得进一步勘探。” 截至发稿时，BRVO 在加拿大的股价上涨了 1.4%。

Price: $3.55, Change: $+0.05, Percent Change: +1.43%

Related Articles

Commodities

Avista Q1 Energy Volumes Drop Across Segments Amid Softer Demand

Avista (AVA) reported Q1 earnings Tuesday, with electricity and natural gas volumes declining as milder weather reduced demand, with residential usage down 10% and commercial down 6%.The company reported total residential electricity sales through its operating unit, Avista Utilities, at 1.15 gigawatt-hours, down from 1.27 GWh a year earlier.Electricity sales to the commercial sector were 768 megawatt-hours for the quarter ended March 31, compared with 808 MWh a year earlier.The company reported industrial electricity sales for 455 MWh for the quarter, down from 469 MWh a year earlier, while wholesale sales were 912 MWh, down from 951 MWh a year earlier.The company reported total residential natural gas sales through its operating unit, Avista Utilities, of 8,490.7 billion British thermal units delivered, down from 9,888.1 billion Btu delivered a year earlier.Commercial natural gas sales were 5,116.1 billion Btu delivered for the quarter ended March 31, compared with 5,961.9 billion Btu delivered a year earlier.The company reported wholesale natural gas volumes of 5,446.1 billion Btu delivered in Q1, down from 6,752.8 billion Btu delivered a year earlier.Other natural gas volumes were 5,446.1 billion Btu delivered for the quarter, compared with 5,401.9 billion Btu delivered a year earlier.Avista is also advancing a new enterprise resource planning system targeted for completion in 2028, with estimated capital expenditures of about $130 million to enhance operational efficiency and financial reporting capabilities.Price: $40.81, Change: $+0.25, Percent Change: +0.62%

$AVA
Australia

Primo Brands' Q1 Faces Pressure From Service Disruptions, Cost Headwinds, RBC Says

Primo Brands (PRMB) is expected to face pressure in Q1 from extended service disruptions tied to winter storms and higher input costs linked to the Middle East conflict, RBC Capital Markets said in a note emailed Tuesday.The firm said Q1 is likely to be the weakest quarter of the year and could be further affected by lost or unrecoverable delivery sales from the winter storms.Retail business trends appear supportive, with sales growth of 6% in scanner data, RBC said, adding that the company has taken pricing on about 15% of its retail volume outside its core case pack business.Primo Brands also remains highly sensitive to petroleum-linked costs, including resin, glass, aluminum and diesel fuel, though it has significant hedge coverage in place for 2026 and levers such as pricing and fuel surcharges, the note said.Primo Brands is expected to report Q1 financial results on Thursday.RBC maintained its outperform rating on Primo Brands and kept its price target at $28.Price: $20.37, Change: $+0.27, Percent Change: +1.37%

$PRMB
Australia

BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth acceleration and market share gains as its expanded enzyme portfolio scales following the acquisition of Amicus Therapeutics (FOLD), Morgan Stanley said in a report Tuesday.In its Q1 results, BioMarin raised its fiscal 2026 revenue guidance to $3.825 billion to $3.925 billion, driven by contributions from newly added therapies Galafold and Pombiliti plus Opfolda, but lowered its non-GAAP earnings per share outlook to $4.85 to $5.05 due to integration-related costs and higher interest expenses, associated with the transaction, the report said.BioMarin is focused on scaling its expanded enzyme portfolio and driving commercial execution, with its management expected to outline a detailed roadmap in Q2 covering "long-term revenue potential," peak sales and cost synergies, the investment bank said.Earnings are expected to be weighted toward the second half of 2026, with the Amicus deal seen by the management as "slightly dilutive" this year but "accretive" within 12 months and more meaningful in start of 2027, the report said.The "combined enzyme portfolio" is expected to support durable growth and help offset rising competition for Voxzogo, while pipeline developments and new launches, including Palynziq expansion and BMN-333, could further support long-term growth, according to the report.Morgan Stanley has an overweight rating on BioMarin Pharmaceutical and lowered its price target to $119 from $120.Price: $54.26, Change: $-1.20, Percent Change: -2.16%

$BMRN$FOLD